Peptides for men are studied across metabolism, body composition, and reproductive health. This guide compares each compound by mechanism, evidence level, and research purpose — so you can evaluate them independently rather than by marketing claims.
A 16-amino acid peptide encoded in mitochondrial DNA. Research focuses on energy regulation, glucose metabolism, stress response, and exercise signalling via AMPK activation.
A mitochondrial-derived peptide under investigation for its role in cellular energy regulation, metabolism, and exercise signalling. Distinct from MOTS-c despite sharing mitochondrial origin.
A short tetrapeptide bioregulator studied in cellular models. Research explores interactions with cell differentiation and potential relationships with reproductive and endocrine pathways. Applications should be drawn from published evidence only.
An experimental growth-hormone fragment variant studied for fat metabolism and body composition. Phase 3 trials did not meet primary endpoints. Mechanism is distinct from full-length GH.
A long-acting amylin analogue explored as an appetite regulator and weight management compound. Studied in combination with semaglutide (CagriSema) in clinical trials.
A melanocortin receptor agonist studied for sexual function. FDA-approved for premenopausal women (Vyleesi); ongoing research in men. Acts centrally via MC3R/MC4R — distinct mechanism from PDE5 inhibitors.
A GHRH analogue that stimulates pituitary GH release. Studied as an alternative to exogenous GH administration. Shorter half-life than CJC-1295.
A ghrelin receptor agonist that stimulates GH release with high selectivity. Often studied in combination with CJC-1295 or sermorelin. No cortisol or prolactin elevation in preclinical models.
Dietary supplements providing protein fragments and amino acids found in connective tissues. Hydrolyzed collagen peptides are processed for absorption — they are not signalling molecules and are not studied for endocrine or metabolic modulation.
When reviewing any compound, verify identity, batch documentation, storage requirements, formulation, and research category independently. These compounds have different targets and are not interchangeable.
| Compound | Primary Target | Category | Human Data |
|---|---|---|---|
| MOTS-c | Mitochondrial AMPK pathway | Metabolic / Longevity | Limited |
| Testagen (KEDG) | HPG/HPT axis bioregulation | Endocrine Research | None (cellular models) |
| AOD-9604 | GH fragment / fat metabolism | Metabolic | Phase 3 (failed endpoints) |
| Cagrilintide | Amylin receptor / appetite | Metabolic / Weight | Phase 2/3 |
| PT-141 | MC3R / MC4R (central) | Sexual Health | Phase 2 (men); approved (women) |
| Sermorelin | GHRH receptor | GH Signalling | Limited |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | GH Signalling | Preclinical only |
| Collagen Peptides | Connective tissue amino acids | Nutritional Supplement | Multiple RCTs (joints/skin) |
Use these criteria to compare peptide compounds for men — mechanism, current evidence level, research objective, and product transparency are the most reliable evaluation framework.
Establish a clear research objective before comparing compounds — different peptides address different mechanisms
Verify the compound name and formulation — many compounds have similar names but distinct structures (e.g., PT-141 vs MT-II)
Examine human and preclinical data independently — preclinical results do not automatically translate to human outcomes
Review third-party testing documentation: COA, HPLC purity data, and batch-specific results
Check for ingredient overlap if evaluating a blend or stack — each component should have a distinct, non-redundant role
Consult a clinician for any health-related application before proceeding
Third-party COA verified. HPLC purity tested. Use code HEALTH for 20% off.
Shop Purgo LabsFor research purposes only. Not for human consumption.
GHK-Cu is the most frequently studied peptide in hair and skin research due to its copper-binding and tissue signalling properties. However, hair loss has multiple causes — hormonal, genetic, nutritional, and inflammatory — and the appropriate research compound depends on the underlying mechanism.
AOD-9604 is a growth-hormone fragment variant (hGH 176-191) being investigated for metabolic use, specifically fat metabolism and body composition. Phase 3 clinical trials did not meet primary endpoints. It is distinct from full-length growth hormone.
A sermorelin-ipamorelin blend combines two compounds that stimulate GH release through different receptor pathways — sermorelin via the GHRH receptor and ipamorelin via the ghrelin receptor (GHS-R1a). The combination is discussed in research and specialist literature for additive GH pulse stimulation.
Cagrilintide is a long-acting amylin analogue studied for appetite regulation and weight management. It has been investigated in combination with semaglutide (the CagriSema combination) in Phase 2/3 trials. It is not a testosterone or hormone support compound.
No. PT-141 (bremelanotide) and MT-II (melanotan II) are both melanocortin receptor agonists but are distinct compounds with different receptor selectivity profiles and different research histories. PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women.
Establish a clear research objective, verify the compound name and formulation, examine human and preclinical data independently, review third-party testing documentation (COA, HPLC), and consult a clinician for any health-related application.